Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Metastatic Prostate Cancer Clinical Trial

Official title:

Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00452387
• Other study ID #: ACORN AVAHRPC0607
• Status: Terminated
• Phase: Phase 2
• First received: March 26, 2007
• Last updated: September 13, 2011
• Start date: May 2007
• Est. completion date: January 2009

Study information

• Verified date: September 2011
• Source: Accelerated Community Oncology Research Network
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to determine if the combination of mitoxantrone, prednisone and sorafenib will improve the time to progression of advanced stage metastatic hormone-refractory prostate cancer.

Description:

The primary objective of this study is to test the hypothesis that the combination of Mitoxantrone, Prednisone and Sorafenib in taxane-refractory patients with metastatic hormone refractory prostate cancer (mHRPC) will result in an improvement of the median time to progression (TTP). Since the median (i.e 50% of patients) TTP for Mitoxantrone/Prednisone is 3 months, our hypothesis is that 70% will have not progressed at 3 months with this investigational combination. Progression will be assessed by radiologic imaging criteria.

The early stopping point is 21 subjects. If 10 or fewer subjects with tumor favorable response are observed when 21 subjects are accrued then the null hypothesis is accepted and the trial is terminated. If 16 or more subjects with tumor favorable response are observed when 21 subjects are accrued then the alternative hypothesis is accepted and the trial is terminated. The probability of early stopping under the null is 0.51, and under the alternative is 0.39. If the trial progresses until 42 subjects are evaluated and 24 or more subjects with favorable response are observed then the null hypothesis is rejected. This design minimizes the average sample number under the null, which is 31.2.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: January 2009
• Est. primary completion date: July 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Voluntary written informed consent

• Histopathologic diagnosis of prostatic adenocarcinoma with evidence of progression despite adequate castration (testosterone < 50 ng/dL)

• Progressive disease after taxane-based chemotherapy (docetaxel or paclitaxel, single agent or combination regimens, weekly or every 21 day schedules)

• Patients who discontinued taxane- based chemotherapy because of toxicity will be eligible as long as there is evidence of progressive disease

• Minimum of 4 weeks period from last chemotherapy infusion to registration (this does not apply to steroid use which is permitted). Estramustine needs to be discontinued at least 6 weeks prior to first day of treatment on protocol

• A minimum of 4 weeks off bicalutamide, nilutamide, megestrol acetate ketoconazole, diethylstilbestrol (DES). Minimum of 2 weeks off flutamide

• Reductase inhibitors will be allowed if initiated at least 2 months prior to registration

• No concurrent investigational therapy

• Complementary and Alternative Medicine (CAM) products will be permitted as long as patients have been receiving them for at least 2 months. Initiation of new CAM products while on protocol will be discouraged.

• Ongoing androgen deprivation therapy (orchiectomy, gonadotropin-releasing hormone (GnRH) agonist or antagonist)

• Adequate bone marrow, liver and renal function as assessed by the following:

• Hemoglobin = 9.0 g/dl

• Absolute neutrophil count (ANC) = 1,500/mm3

• Platelet count = 100,000/mm3

• Total bilirubin = 1.5 times upper limit of normal (ULN)

• ALT and AST = 2.5 times the ULN ( = 5 x ULN for patients with liver involvement)

• Creatinine = 1.5 times the ULN

• International normalized ratio (INR) < 1.5 or a Prothrombin (PT)/Partial thromboplastin time (PTT) within normal limits. Patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stable.

• ECOG performance status = 2

• Baseline left ventricular ejection fraction (LVEF) = 50%

• Life expectancy = 3 months

• Patients must agree to use adequate contraception prior to study entry, during the study and for at least three months after the last administration of sorafenib

Exclusion Criteria:

• More than one line of prior cytotoxic chemotherapy in the metastatic setting, previous adjuvant chemotherapy will be allowed

• No active malignancy other than prostate cancer (except non-melanoma skin cancer) within 5 years of enrollment

• Known brain metastases

• Cardiac disease: Congestive heart failure > class II New York Heart Association (NYHA). Patients must not have unstable angina or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months

• Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

• Uncontrolled hypertension

• Active clinically serious infection > Common Terminology Criteria for Adverse Events (CTCAE) Grade 2

• Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months

• Pulmonary hemorrhage/bleeding event = CTCAE Grade 2 within 4 weeks of first dose of study drug

• Any other hemorrhage/bleeding event = CTCAE Grade 3 within 4 weeks of first dose of study drug

• Poorly controlled hyperglycemia

• Treatment with radiotherapy within 4 weeks or treatment with radiopharmaceuticals within past 8 weeks

• Patient has received other investigational drugs within 14 days before enrollment

• Serious medical or psychiatric illness likely to interfere with participation in this clinical study

• Serious non-healing wound or ulcer

• Evidence or history of bleeding diathesis or coagulopathy

• Use of St. John's Wort or rifampin

• Known or suspected allergy to sorafenib or any agent given in the course of this trial

• Any condition that impairs patient's ability to swallow whole pills

• Any malabsorption problem

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Metastatic Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Mitoxantrone
Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion. Dose Level -2, Mitoxantrone 9mg/m2 Dose Level -1 Mitoxantrone 12mg/m2 Dose Level 1 Mitoxantrone 12mg/m2
• Prednisone
Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion. Dose Level -2, Prednisone 5mg bid Dose Level -1 Prednisone 5mg bid Dose Level 1 Prednisone 5mg bid
• Sorafenib
Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion. Dose Level -2, Sorafenib 400 mg QD Dose Level -1 Sorafenib 400 mg QD Dose Level 1 Sorafenib 400 mg bid

Locations

Country	Name	City	State
United States	Peachtree Hematology Oncology Consultants	Atlanta	Georgia
United States	Hematology Oncology Centers of the Northern Rockies, PC	Billings	Montana
United States	Cancer Specialists of Tidewater	Chesapeake	Virginia
United States	Mid-Ohio Oncology/Hematology, Inc.	Columbus	Ohio
United States	Wilshire Oncology Medical Group, Inc.	La Verne	California
United States	Lancaster Cancer Center	Lancaster	Pennsylvania
United States	Central Georgia Cancer Care	Macon	Georgia
United States	Northwest Georgia Oncology Centers	Marietta	Georgia
United States	The West Clinic	Memphis	Tennessee
United States	Pennsylvania Oncology Hematmology Associates	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Accelerated Community Oncology Research Network	Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Median Time to Progression (TTP) by Imaging	Time to progression is defined as the time from treatment start until objective tumor progression. The median time to progression is the parameter used to describe TTP.	Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.	No
Secondary	Correlation of Biochemical Criteria (PSA, Prostate-specific Antigen) With Objective Imaging	The test of association assesses the null hypothesis that the frequency of PSA response is the same for patients with and without a favorable imaging response. PSA response required a 50% reduction of the baseline PSA result that was confirmed three weeks later. Favorable imaging response is defined as stable disease, partial response, or complete response per RECIST guidelines. The Fisher's exact test was used to test this hypothesis.	PSA was evaluated on day 1 of every cycle (approximately every 3 weeks) during study treatment. Radiologic imaging was repeated after every 4 cycles (approximately every 12 weeks) during study treatment.	No
Secondary	Quality of Life (QoL)	The subject answers questions from the following 6 categories: general physical symptoms, treatment side effects, distress, despair, impaired performance, and impaired ambulation. Each question has a scale from 0 through 10, where 0 is not a problem and 10 is as bad as possible. The scores for the 6 categories are combined and normalized, and used to describe overall quality of life. Because normalized scores are created using a look-up index, there is no clearly defined maximum value. In practice, the maximum value for the combined scale is 73.5.	The Patient Care Monitor questionnaire was administered on day 1 of every cycle (approximately every 3 weeks) during study treatment.	No
Secondary	Median Overall Survival (OS)	Overall survival is defined as the time from treatment start until death from any cause. The median overall survival time is used to measure OS.	Overall survival was measured from day 1 of treatment until the end of treatment and then every 3 months thereafter until death.	No